Theragen Etex Co.Ltd
Theragen Etex Co.,Ltd., together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products. It offers drugs in the fields of circulatory, respiratory, digestive, antibiotics, antifungals, analgesic, endocrine and metabolic, hepatoprotective, psychotropic, urinary system, skeletal muscle, PMS, anthelmintic, nutrition, and others. The company wa… Read more
Theragen Etex Co.Ltd (066700) - Total Assets
Latest total assets as of September 2025: ₩245.25 Billion KRW
Based on the latest financial reports, Theragen Etex Co.Ltd (066700) holds total assets worth ₩245.25 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Theragen Etex Co.Ltd - Total Assets Trend (2005–2024)
This chart illustrates how Theragen Etex Co.Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Theragen Etex Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Theragen Etex Co.Ltd's total assets of ₩245.25 Billion consist of 63.6% current assets and 36.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 9.4% |
| Accounts Receivable | ₩63.72 Billion | 26.9% |
| Inventory | ₩35.83 Billion | 15.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩7.30 Billion | 3.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how Theragen Etex Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Theragen Etex Co.Ltd's current assets represent 63.6% of total assets in 2024, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 9.4% of total assets in 2024, down from 27.9% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 26.9% of total assets.
Theragen Etex Co.Ltd Competitors by Total Assets
Key competitors of Theragen Etex Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AGP Ltd
KAR:AGP
|
Pakistan | PKRs28.27 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
DongKoo Bio&Pharma Co. Ltd
KQ:006620
|
Korea | ₩269.00 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Sam-A Pharm. Co. Ltd
KQ:009300
|
Korea | ₩246.13 Billion |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040
|
Korea | ₩291.47 Billion |
|
WooGene B&G Co. Ltd
KQ:018620
|
Korea | ₩117.10 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩154.14 Billion |
Theragen Etex Co.Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Theragen Etex Co.Ltd generates 1.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Theragen Etex Co.Ltd is currently not profitable relative to its asset base.
Theragen Etex Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.75 | 1.27 | 1.48 |
| Quick Ratio | 1.38 | 0.94 | 1.17 |
| Cash Ratio | 0.00 | 0.27 | 0.00 |
| Working Capital | ₩69.58 Billion | ₩ 26.76 Billion | ₩ 31.10 Billion |
Theragen Etex Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Theragen Etex Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.83 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -2.5% |
| Total Assets | ₩237.00 Billion |
| Market Capitalization | $47.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values Theragen Etex Co.Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Theragen Etex Co.Ltd's assets decreased by 2.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Theragen Etex Co.Ltd (2005–2024)
The table below shows the annual total assets of Theragen Etex Co.Ltd from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩237.00 Billion | -2.52% |
| 2023-12-31 | ₩243.14 Billion | -1.39% |
| 2022-12-31 | ₩246.55 Billion | -29.57% |
| 2021-12-31 | ₩350.07 Billion | -34.55% |
| 2020-12-31 | ₩534.89 Billion | +121.49% |
| 2019-12-31 | ₩241.50 Billion | +38.25% |
| 2018-12-31 | ₩174.68 Billion | +20.12% |
| 2017-12-31 | ₩145.42 Billion | +3.17% |
| 2016-12-31 | ₩140.96 Billion | +2.20% |
| 2015-12-31 | ₩137.93 Billion | +9.73% |
| 2014-12-31 | ₩125.69 Billion | +3.91% |
| 2013-12-31 | ₩120.96 Billion | +6.27% |
| 2012-12-31 | ₩113.82 Billion | +13.64% |
| 2011-12-31 | ₩100.16 Billion | +2.16% |
| 2010-12-31 | ₩98.05 Billion | +11.04% |
| 2009-12-31 | ₩88.30 Billion | +19.48% |
| 2008-12-31 | ₩73.91 Billion | +39.75% |
| 2007-12-31 | ₩52.89 Billion | +24.01% |
| 2006-12-31 | ₩42.65 Billion | -6.87% |
| 2005-12-31 | ₩45.79 Billion | -- |